Ix Biopharma’s Share Slide: 6.45% Drop Highlights Pipeline & Liquidity Risks
Ix Biopharma’s share plunge reveals deeper risk: thin liquidity, a costly, unproven pipeline, and steep loss to its 200‑day SMA—why investors should pause.
3 minutes to read